The clinical significance of atypical glands suspicious for malignancy (atypia) on prostate biopsy is unclear. We studied a cohort of 139 patients with atypia who underwent repeat prostate biopsy. We analyzed clinical and pathological variables that may be associated with cancer on repeat biopsy. Cancer was diagnosed in 41 (29%) of patients with atypia: 26 of 41 (66%) were Gleason 6, 20% were Gleason 7 and 7% were Gleason 8 (Gleason o6 not reported). There were no significant associations of age, race, family history, PSA, PSA density (PSAd), number of previous biopsies or time to repeat biopsy with cancer diagnosis. In multivariate regression, histological inflammation was associated with an 85% decreased probability of cancer on repeat biopsy (odds ratio; OR 0.15; 95% confidence interval; CI 0.04-0.57; P ¼ 0.04). Radical prostatectomy was performed in 14 of 41 (34%) patients with cancer; 6 (43%) were Gleason sum X7, 3 (21%) were pT3a and 1 (7%) had lymph node metastases. In conclusion, inflammation was independently associated with a significantly decreased risk of cancer on repeat biopsy. However, some patients with initial atypia have higher-risk prostate cancer. Additional studies are needed to elucidate these associations.
Introduction
Atypical glands suspicious for malignancy (atypia) are a relatively common pathological finding on prostate biopsy. Also called atypical small acinar proliferation, atypia is a term for small foci that are suspicious for, but not diagnostic of, adenocarcinoma. The prevalence of atypia on initial prostate biopsy is B5%. 1 Prostate cancer screening has led to roughly 1 000 000 prostate biopsies yearly in the United States of America. 2 Based on a 5% prevalence of atypia, it is estimated that 50 000 new cases will be diagnosed yearly, each of which will require a repeat biopsy to evaluate for malignancy. Although there is B40% probability of detecting cancer on repeat biopsy for atypia, cancer prevalence varies widely from one study population to another: 17-70%. [1] [2] [3] [4] [5] Potential explanations for this variation include small sample sizes, variable biopsy schema, diagnostic biases and disparate patient populations. [3] [4] [5] Current recommendations are that, because of the relatively high probability of cancer, repeat biopsy is indicated after diagnosis of atypia. 6 However, clinical and pathological variables associated with diagnosis of cancer on repeat biopsy for atypia have not been defined. Further investigation of these variables may elucidate connections of atypia with cancer diagnosis and thus lead to refinements in clinical care. We investigated the clinical and pathological characteristics of patients who underwent repeat biopsy for atypia found on initial prostate biopsy, analyzed variables associated with cancer on repeat biopsy and reviewed the pathological findings of patients who underwent prostatectomy.
Patients and methods
We conducted an IRB-approved retrospective review of patients at the VA San Diego Medical Center who were diagnosed with atypia on transrectal ultrasound-guided prostate biopsy from December 1999 through October 2009. We defined atypia as glands suspicious for, but not diagnostic of, malignancy. We included patients with atypia who underwent at least one repeat biopsy and excluded those with concurrent prostate cancer on initial biopsy or known prostate cancer on active surveillance.
Clinical and pathological characteristics were retrospectively collected and analyzed for patients who met inclusion criteria. Clinical variables included age, body mass index, race, family history of prostate cancer, indication for initial biopsy (abnormal digital rectal exam, elevated PSA), serum PSA value, history of previous biopsy, finasteride use and duration, number of cores obtained at biopsy, prostate volume, PSA density (PSAd) and time interval to repeat biopsy. Pathological variables included Gleason sum (when a diagnosis of cancer was made) and histological presence of inflammation. Pathological diagnoses of inflammation and atypia are prospectively recorded as standard practice of our pathology department. An attending pathologist reviews each case. Atypia cases are evaluated with immunohistochemical staining and reviewed by more than one pathologist. Cases with any uncertainty are internally reviewed during pathology department conferences. Year of atypia diagnosis was recorded and used in our analysis to account for possible variations in biopsy techniques and pathology diagnostic criteria over time. We chose 2004 as the transition point because this was closest to the median year of diagnosis. We also collected data for patients with atypia who did not undergo repeat biopsy to account for possible uncertainty in our statistical outcomes. Sensitivity analysis was performed to determine whether the results would have been significantly different if these patients had undergone repeat biopsy.
Univariate analysis compared data between patients with atypia who did and did not undergo repeat biopsy to evaluate for possible bias. We compared data between those with and without prostate cancer on repeat biopsy. Multivariate analysis was performed using a logistic regression model, including clinically relevant parameters, for predicting the development of cancer on repeat biopsy. Pathological outcomes were analyzed in patients with prostate cancer on repeat biopsy who subsequently underwent radical prostatectomy, 
Results

Study population
Between December 1999 and October 2009, the pathology department examined 6463 prostate specimens of 2640 patients at the VA San Diego Healthcare System. We identified 379 patients with prostate atypia. We excluded 12 of the 379 patients whose prostate specimens were not from biopsies (diagnosed on TURP or cystoprostatectomy).
We excluded 168 of the 379 patients for concurrent or previous diagnosis of prostate cancer. This resulted in 199 of 2628 (7.6%) patients with atypia alone on biopsy. There were 60 of the 199 patients who did not undergo repeat biopsy and were recorded as a separate group to analyze for bias. Our final cohort included the remaining 139 patients, who did not have concurrent or previous cancer diagnosis and who underwent a repeat biopsy after diagnosis of atypia.
Demographic and clinical data for the 139 patients who did undergo repeat biopsy were compared with data for the 60 who did not. There were no significant differences in age, body mass index, race, family history of prostate cancer, history of previous biopsy or year of atypia diagnosis (Table 1) . Those who did not undergo repeat biopsy had significantly lower PSA (5.0 (IQR 3.3-7.4) ng ml À1 versus 4.4 (IQR 1.4-6.4) ng ml À1 , P ¼ 0.019) and significantly lower PSAd (0.08 (IQR 0.06-0.13) ng ml
Similarly, the percentage of patients whose initial biopsy was indicated by elevated PSA was significantly lower among those who did not undergo repeat biopsy (repeat: elevated PSA 72%, abnormal digital rectal exam 24%, both 4%; versus no repeat: elevated PSA 51%, abnormal digital rectal exam 41%, both 8%; P ¼ 0.014). Histological inflammation was significantly lower in the group who did not undergo repeat biopsy (42 versus 62%, P ¼ 0.008). Repeat biopsy led to a diagnosis of prostate cancer in 29% (41/139) of the patients. Grade on repeat biopsy was Gleason sum 6 for 66%, Gleason sum 7 for 20% and Gleason sum 8 for 7% (Gleason o6 not reported). Prostate atypia and cancer diagnosis on repeat biopsy RP Kopp et al
For patients who underwent repeat biopsy, there were no significant differences between those with and those without cancer in age, body mass index, race, family history of prostate cancer, indication for biopsy, history of previous biopsy, PSA, PSAd, prostate volume, time to repeat biopsy, year of atypia diagnosis or number of biopsy cores obtained (Table 2) . Those with cancer were significantly less likely to have inflammation present on the initial biopsy (41 versus 70%, P ¼ 0.003). There was no difference in PSA among those with and those without inflammation who underwent repeat biopsy (data not shown). However, patients who did not undergo repeat biopsy had a significantly lower proportion of inflammation (25/60, 42%; Table 1 ); therefore, we performed sensitivity analysis to evaluate for uncertainty of the inverse association between inflammation and cancer. We determined that 19 of these 25 (76%) patients with inflammation who did not undergo biopsy would require cancer diagnosis on repeat biopsy for the inverse association of histological inflammation and cancer to become statistically insignificant. Of note, patients with cancer were also less likely to be on finasteride (2% (1/41) versus 16% (16/98), P ¼ 0.02; data not shown).
Regression models
To identify variables associated with prostate cancer on re-biopsy, multivariable analysis was performed using a logistic regression model for predicting the development of cancer on repeat biopsy (Table 3) . Histological inflammation was associated with decreased probability of cancer on repeat biopsy; this association remained significant in multivariable logistic regression analysis with an 85% decrease in diagnosis of cancer when inflammation was present (odds ratio; OR 0.15, 95% confidence interval; CI 0.04 to 0.57, P ¼ 0.005). Year of atypia diagnosis was included in the analysis to account for possible variation in biopsy technique and pathological criteria for diagnosis. There was no association between year and diagnosis of cancer. Finasteride use was limited and, therefore, not included.
Radical prostatectomy
Fourteen patients initially found to have prostate cancer on repeat biopsy underwent radical prostatectomy, eight with pelvic lymph node dissection (Table 4) . Biopsy revealed Gleason sum 6 or less in eight (57%) patients, Gleason 7 in five (36%) patients and Gleason 8 in one (7%) patient. Additionally, 29% (4/14) upgraded on final pathology. Pathological stage of the primary tumor revealed 2 (14%) pT2a, 2 (14%) pT2b, 7 (50%) pT2c, and 3 (21%) pT3a. Notably, 79% (11/14) were upstaged from their repeat biopsy. Final pathological staging revealed node positivity (N1) in one of eight patients who underwent pelvic lymph node dissection. 7 reported a positive association with PSA level and risk of cancer diagnosis in patients with atypia. The authors proposed that the association was not seen previously because PSA was not used as a continuous variable in other studies; however, the Borboroglu study included PSA level as a continuous variable in their multivariate model and there was no association between PSA and cancer risk in atypia patients. 4 Similarly, we repeated our logistic regression analysis with PSA as a continuous variable (log (PSA)), without any significant findings (OR 7.2, 95% CI 0.31-168, P ¼ 0.219), despite a relatively large PSA range of 0.27-37.1 ng ml À1 (data not shown). This is the largest atypia cohort to date to report PSAd, which did not significantly differ between groups ( , with and without cancer). PSAd may have been associated with the lower prevalence of malignancy (29%) in this cohort compared with others. [1] [2] [3] [4] [5] Furthermore, the relatively low PSAd of patients undergoing repeat biopsy is primarily due to the large prostate volume (60.1 cc)-a variable which is associated with decreased incidence of detecting cancer on prostate biopsy 8-10 -although we did not identify a significant trend between prostate volume and cancer diagnosis within our cohort. The cancer prevalence in this cohort is slightly higher than the risk of cancer on repeat biopsy following a benign diagnosis-B23% when combining modern studies using various biopsy techniques. 1 Additionally, various studies suggest that diagnostic sensitivity of prostate biopsy might not exceed B30% in most situations, even if saturation biopsy is performed. [11] [12] [13] [14] These studies are not specific to atypia patients, but they illustrate possible limitations of prostate biopsy, particularly when combined with other studies documenting the limitations of biopsying large prostates, and may contribute to the lower cancer prevalence in this cohort. Although our cohort underwent heterogeneous core sampling, the association with cancer diagnosis was not statistically significant (Table 2) .
Furthermore, our data demonstrate that inflammation was associated with decreased risk of cancer (OR 0.15, 95% CI 0.04-0.57, P ¼ 0.005; Table 3 ). As inflammation is believed to be an important component in the genesis of prostate cancer, 15 the association of inflammation with a decreased risk of malignancy is a potentially counterintuitive observation. Still, this finding is consistent with other studies.
3, 16 Karakiewicz et al. reviewed 4526 initial prostate biopsies and noted that chronic inflammation was inversely associated with prostate cancer (OR 0.19, 95% CI 0.13-0.27), and this was independent of PSA and gland volume. They also noted an inverse association with high-grade prostatic intraepithelial neoplasia (OR 0.11, 95% CI 0.05-0.22), although atypia was not recorded in the study. 16 We identified one study investigating this relationship in atypia patients undergoing repeat biopsy; the authors noted a decreased prevalence of cancer with inflammation-although the prevalence of inflammation in that cohort (39% overall, 23% with cancer versus 51% without cancer, (P ¼ 0.05)) was lower. 3 As mentioned previously, some of our patients with atypia and inflammation did not undergo repeat biopsy; these men had significantly lower PSA and less inflammation compared with those who underwent repeat biopsy. Sensitivity analysis determined that cancer would have to be diagnosed in 76% of the men with inflammation who did not undergo repeat biopsy for our results to be rendered statistically insignificant; this would be highly unlikely based on clinical characteristics of the patients (Table 1 ) and the diagnostic sensitivity of prostate biopsy. [12] [13] [14] Moreover, although men who did not undergo repeat biopsy had less inflammation and lower PSA, there was no association between inflammation and PSA among patients who did undergo repeat biopsy. Although there was no pathology review for this study, any variability in the prospective diagnosis of inflammation and cancer may be non-differential and thus not substantially alter the findings. Prostate atypia and cancer diagnosis on repeat biopsy RP Kopp et al
One potential explanation for the lower risk of prostate cancer with inflammation (Table 3) is that-as a diagnosis of atypia may result from a distortion of normal tissue in a biopsy core-inflammation may confound an initial biopsy diagnosis by altering cellular architecture in a specimen that otherwise would appear unremarkable. Another potential explanation is that inflammation is also associated with BPH. AbdelMeguid and colleagues investigated the relationship between inflammation, BPH and prostate cancer and noted that concurrent inflammation and BPH was more prevalent than concurrent inflammation and cancer (20 versus 15%) . 17 Similarly, in a histopathological review of 3942 patients, Di Silverio and colleagues reported that inflammation was associated with BPH in 43% and that there was no statistically significant correlation between inflammation and incidental carcinoma. 18 Larger prostates are associated with not only inflammation, 18 but also lower risk of Gleason upgrading 19, 20 and lower incidence of cancer. 10 This suggests there may be a complex underlying relationship between BPH, cancer and inflammation.
A growing body of evidence supports that inflammation modulates BPH progression. 21, 22 Quintar et al. recently demonstrated that acute inflammation secondary to infection resulted in upregulation and hypertrophy of prostatic epithelial and stromal components. 22 The authors noted smooth muscle hypertrophy, with eventual dedifferentiation into a secretory phenotype, which they postulate may have a role in protection against infection. Furthermore, they allude to the potentially complex immune-regulatory pathways that may promote a BPH or cancer phenotype if sustained signals are present. 22 Theoretically, inflammatory-induced stromal changes that protect against infectious microorganisms may potentially decrease cancer risk from viruses shown to have an association with cancer (which have not been associated with BPH), such as xenotropic murine leukemia-related virus. [23] [24] [25] Inflammatory infiltrates in BPH demonstrate a shift towards predominantly activated CD4( þ ) T lymphocytes and a milieu of proinflammatory cytokines. 21 This may have implications to and beyond the atypia population.
It is not known whether atypia on initial biopsy influences clinical or pathological outcomes. The current literature lacks studies with sufficient population size and length of follow-up to adequately describe outcomes for these patients. In a previous series, Brausi and colleagues studied 25 patients who underwent immediate prostatectomy for an initial diagnosis of atypia. All of them had prostate adenocarcinoma on final diagnosis, the majority (84%) with Gleason sum p6. 26 Although in our cohort the majority (57%) of patients who underwent prostatectomy had a final pathological grade of Gleason sum p6, a substantial proportion were Gleason sum X7, pT3, and/or lymph node positive. These data suggest that a substantial amount of intermediate-or high-risk disease may be present in patients with atypia on initial biopsy, although our sample size was limited. Sampling error may have contributed to an initial diagnosis of atypia in some men with more significant cancer; however, the proportion of patients with Gleason sum 46 on biopsy (27%) was nearly identical to the placebo arm in REDUCE. 10 Furthermore, 4 of 14 (29%) patients were upgraded at prostatectomy, which is well within reported rates of upgrading (40-50%) in other radical prostatectomy populations. 19, 20 Our study reports one of the largest atypia cohorts to date and spans nearly 10 years. This VA population consists of patients with multiple care providers, both within and outside the system. Although our analysis is limited by the retrospective nature of the study, we found no significant differences based on year of diagnosis. Additionally, the fraction of patients with atypia who did not undergo repeat biopsy was similar to other populations 3 and was similar in demographic characteristics to those who did undergo repeat biopsy. Our study demonstrates a need to further characterize risk factors for patients with atypia, their long-term outcomes and the role of inflammation in both BPH and prostate cancer. We used presence or absence of histological inflammation as a variable in our analysis. Although a histopathological classification system has been developed for prostatic inflammation-which includes anatomical location, extent and grade-the authors of the classification system comment on the large amount of conflicting data regarding possible associations between these criteria and PSA elevation, clinical symptoms of BPH or relationship to prostate cancer. 27 Moreover, immunohistochemical stains which differentiate markers of cellular proliferation and inflammatory cell types may be more meaningful in future analyses of inflammation and prostatic disease. 21, 27 In conclusion, histological inflammation is associated with a lower prevalence of prostate cancer on repeat biopsy for atypia. Patients with atypia on initial biopsy may have clinically significant intermediate-to high-risk prostate cancer. Additional studies are needed to validate these findings and further explain these associations.
